Influence of adiposity on inflammation risk in patients with fasting glucose impairment
Keywords:
Diabetes mellitus, Oxidative stress, Inflammation, ObesityAbstract
Objective
The objective of this study was to investigate changes in inflammatory markers in obese individuals with impaired fasting glucose.
Methods
The following data of 125 adult individuals were assessed: body mass index, waist circumference, fasting glucose, high-sensitivity c-reactive protein, uric acid and homocysteine. The groups with normal fasting glucose (group 1) and impaired fasting glucose (group 2) were compared with each other and with their subgroups, which consisted of obese, overweight and normal-weight individuals.
Results
Group 2 presented greater waist circumferences (p<0.05), especially when associated with excess weight. Additionally, group 2 had higher C-reactive protein and uric acid values than group 1 and the obese in group 2 had higher C-reactive protein and uric acid than the overweight and normal-weight individuals of the same group. On the other hand, homocysteine levels were similar in all individuals, regardless of weight. Body mass index correlated positively with both uric acid (r=0.39, p<0.01) and C-reactive protein (r=0.37, p<0.01). Waist circumference correlated only with uric acid (r=0.53, p<0.01). However, the correlation between body mass
index and C-reactive protein was significant in group 2 (r=0.66, p<0.01) but not in group 1 (r=0.25, p>0.05). The same occurred regarding waist circumference and C-reactive protein, which correlated significantly only in the presence of impaired fasting glucose (r=0.40, p<0.05). In logistic regression, waist circumference was the independent variable (11%, p<0.01) of impaired fasting glucose.
Conclusion
Pro-oxidative and pro-inflammatory states were significantly associated with impaired fasting glucose in the presence of body fat.
References
Sriraman R, Tooke JE. Endothelial dysfunction and insulin resistance. Metab Synd Relat Disord. 2004; 2(2):129-36.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes. 2003; 52(1):1-8.
Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care. 2003; 26(5): 1589-96.
Coppola A, Astarita C, Oliviero M, Fontana D, Picardi G, Esposito K, et al. Impairment of coronary circulation by acute hyperhomocysteinemia in type 2 diabetic patients. Diabetes Care. 2004; 27(8): 2055-6.
Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab. 2004; 1(10): 1-10.
Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawia T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003; 41(6):1287-93.
Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel’ova J, Olejnikova M. Uric acid: a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr. 2002; 114 (5-6):211-5.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001; 286(3):327-34.
Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003; 929(4B): 17k-22k.
Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004; 2(2):82-104.
Kolb K, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005; 48(6): 1038-50.
Festa A, D’Agostino Jr R, Hanley AJG, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004; 53(6):1549-55.
Fonseca-Alaniz MH, Takada J, Alonso-Vale MIC, Lima BF. O tecido adiposo como centro regulador do metabolismo. Arq Bras Endocrinol Metab. 2006; 50(2):216-28.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005; 28(1):S37-S42.
World Health Organization. Diet, nutrition and the prevention of chronic diseases. Geneva: WHO; 2002.
Friedewald TW, Levy RI, Friederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502.
Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH- LIGA homocystein (German, Austrian and Swiss homocysteine society): Consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003; 41(11):1392-403.
Salles JF, Bloch KV, Cardoso CRL. Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. Diabetes Care. 2004; 27(6): 1299-305.
Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004; 79(3):379-84.
Wong SL, Janssen I, Ross R. Abdominal adipose tissue distribution and metabolic risk. Sports Med. 2003; 33(10):709-28.
Tanrikulu-Kiliç F, Bekpinar S, Ünlüçerçi Y, Orhan Y. Insulin resistance is not related to plasma homocysteine concentration in healthy premenopausal women. Physiol Res. 2006; 55(3):285-90.
Schäfer SA, Müssig K, Stefan N, Häring HU, Fritsche A, Balletshofer BM. Plasma homocysteine concentrations in young individuals at increased risk of type 2 diabetes are associated with subtle differences in glomerular filtration rate but not with insulin resistance. Exp Clin Endocrinol Diabetes. 2006; 114(6):306-9.
Hall JE, Brands MW, Henegar JR. Mechanism of hypertension and kidney disease in obesity. Ann N Y Acad Sci. 1999; 892(11):91-107.
Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens. 2001; 19(7):1209-15.
Niskanen LK, Laaksonen DE, Nyysönen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort. Arch Intern Med. 2004; 164(14):1546-51.
Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005; 118(8):816-26.
Moran A, Steffen LM, Jacobs DR Jr, Steinberger J, Pankow JS, Hong CP, et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care. 2005; 28(7): 1763-8.
Campos WP, Baumann H. Insulin is a prominent modulator of the cytokine stimulated expression of acute-phase plasma protein genes. Mol Cell Biol. 1992; 12(4):1789-97.
Mota JF, Medina WL, Moretto F, Burini RC. Nutritional and metabolic determinants of insulin resistance in adults. FASEB J. 2007; 21(837.4): A1068.
Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008; 14(11-12):741-51.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 João Felipe MOTA, Wilson Luvizotto MEDINA, Fernando MORETO MORETO, Roberto Carlos BURINI
This work is licensed under a Creative Commons Attribution 4.0 International License.
